Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 7, 2025 | $0.34 | 2025-03-31 | 2025-03-31 |
| December 12, 2024 | $0.33 | 2024-09-30 | 2024-09-30 |
| July 8, 2024 | $0.29 | 2024-03-27 | 2024-03-28 |
| December 11, 2023 | $0.32 | 2023-09-28 | 2023-09-29 |
| July 10, 2023 | $0.31 | 2023-03-30 | 2023-03-31 |
Dividends Summary
- Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has issued 13 dividend payments over the past 6 years
- The most recent dividend was paid 75 days ago, on July 7, 2025
- The highest dividend payed out to investors during this period was $0.430533 per share
- The average dividend paid during this period was $0.36 per share.
Company News
The immune thrombocytopenic purpura (ITP) market is expected to grow at a 1.9% CAGR from 2025-2034, with Sanofi's WAYRILZ approval marking a significant shift in treatment options and sparking competition among pharmaceutical companies developing novel therapies.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
Protagonist Therapeutics reported Q2 2025 financial results, highlighting progress in clinical pipeline with rusfertide and icotrokinra drug candidates, while experiencing lower-than-expected revenue but maintaining strong cash reserves through 2028.
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.